NOX Share Price History
11 May, 2021
Noxopharm begins first-line sarcoma treatment testing for Veyonda.
27 Apr, 2021
Interim data in the NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with COVID-19.
14 Apr, 2021
Noxopharm files septic shock treatment patent for Veyonda®
18 Mar, 2021
Noxopharm Limited announced Veyonda has been approved to move into the second and final stage of the NOXCOVID-1 clinical trial.
17 Feb, 2021
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
03 Dec, 2020
Noxopharm announces a discovery by Cornell Medical College published in Nature Immunology validating the novel DARRT anti-cancer treatment of Veyonda®
12 Nov, 2020
Noxopharm announces pilot study with Bristol Myers Squibb’s product
10 Sep, 2020
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
23 Jul, 2020
Noxopharm has claimed a breakthrough in the search for restoring immune function within "cold" microtumors, converting them to so-called "hot" tumors.